American Society of Hirudotherapy

Leech Extract Cardiovascular Pharmacology (2022 Review)

Review of leech extract's cardiovascular and atherosclerotic pharmacological effects in animal + cell models — May 2022.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Last Updated: May 28, 2026 · ASH Editorial · based on the books

Mechanistic Evidence Box

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.
Page type
Compound profile
Evidence type
Preclinical / biochemical characterization
Evidence level
Expert consensus
Drug vs leech
Leech-derived crude extract
Safety domains
Bleeding

Clinical translation limit

Review evidence does NOT establish clinical efficacy in humans for atherosclerosis or cardiovascular disease. Not an FDA-cleared indication.

Molecular Profile

Category
Other
Evidence tier
Preclinical
Source species
Hirudo medicinalis / Hirudo nipponia / Whitmania pigra (composite)
Discovered
2022 · Khan T et al.

Biological Targets

  • → thrombus formation; platelet aggregation; atherosclerotic plaque; vascular endothelium

Key Citations

  1. Wang K et al. (2022), J Ethnopharmacol · PMID 35589020

External Resources

    Related Other Compounds

    This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.